World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat

Hidekazu Suzuki; Hideki Mori

doi:10.1007/s00535-017-1407-1

World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat

Hidekazu Suzuki, Hideki Mori

Medical Education Center

Research output: Contribution to journal › Review article › peer-review

93 Citations (Scopus)

Abstract

Helicobacter pylori-associated gastritis leads to the development of gastric cancer. Kyoto global consensus report on H. pylori gastritis recommended H. pylori eradication therapy to prevent gastric cancer. To manage H. pylori infection, it is important to choose the appropriate regimen considering regional differences in resistance to clarithromycin and metronidazole. Quinolones and rifabutin-containing regimens are useful as third- and fourth-line rescue therapies.

Original language	English
Pages (from-to)	354-361
Number of pages	8
Journal	Journal of gastroenterology
Volume	53
Issue number	3
DOIs	https://doi.org/10.1007/s00535-017-1407-1
Publication status	Published - 2018 Mar 1

Keywords

Clarithromycin
Fluoroquinolone
Gastric cancer
H. pylori
Metronidazole

ASJC Scopus subject areas

Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00535-017-1407-1

Cite this

@article{c0eca67e5de346c0a735ec2f6f83d0b6,

title = "World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat",

abstract = "Helicobacter pylori-associated gastritis leads to the development of gastric cancer. Kyoto global consensus report on H. pylori gastritis recommended H. pylori eradication therapy to prevent gastric cancer. To manage H. pylori infection, it is important to choose the appropriate regimen considering regional differences in resistance to clarithromycin and metronidazole. Quinolones and rifabutin-containing regimens are useful as third- and fourth-line rescue therapies.",

keywords = "Clarithromycin, Fluoroquinolone, Gastric cancer, H. pylori, Metronidazole",

author = "Hidekazu Suzuki and Hideki Mori",

note = "Funding Information: During the last 2 years, H.S. received scholarship funds for the research from Daiichi-Sankyo Co., Otsuka Pharmaceutical Co. Ltd., and Tsumura Co., and received service honoraria from Astellas Pharma Inc, AstraZeneca K.K., Daiichi-Sankyo Co., Otsuka Pharmaceutical Co. Ltd., Mylan EPD Co., Takeda Pharmaceutical Co., Ltd., and Zeria Pharmaceutical Co. Ltd. Publisher Copyright: {\textcopyright} 2017, The Author(s).",

year = "2018",

month = mar,

day = "1",

doi = "10.1007/s00535-017-1407-1",

language = "English",

volume = "53",

pages = "354--361",

journal = "Journal of Gastroenterology",

issn = "0944-1174",

publisher = "Springer Japan",

number = "3",

}

TY - JOUR

T1 - World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat

AU - Suzuki, Hidekazu

AU - Mori, Hideki

N1 - Funding Information: During the last 2 years, H.S. received scholarship funds for the research from Daiichi-Sankyo Co., Otsuka Pharmaceutical Co. Ltd., and Tsumura Co., and received service honoraria from Astellas Pharma Inc, AstraZeneca K.K., Daiichi-Sankyo Co., Otsuka Pharmaceutical Co. Ltd., Mylan EPD Co., Takeda Pharmaceutical Co., Ltd., and Zeria Pharmaceutical Co. Ltd. Publisher Copyright: © 2017, The Author(s).

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Helicobacter pylori-associated gastritis leads to the development of gastric cancer. Kyoto global consensus report on H. pylori gastritis recommended H. pylori eradication therapy to prevent gastric cancer. To manage H. pylori infection, it is important to choose the appropriate regimen considering regional differences in resistance to clarithromycin and metronidazole. Quinolones and rifabutin-containing regimens are useful as third- and fourth-line rescue therapies.

AB - Helicobacter pylori-associated gastritis leads to the development of gastric cancer. Kyoto global consensus report on H. pylori gastritis recommended H. pylori eradication therapy to prevent gastric cancer. To manage H. pylori infection, it is important to choose the appropriate regimen considering regional differences in resistance to clarithromycin and metronidazole. Quinolones and rifabutin-containing regimens are useful as third- and fourth-line rescue therapies.

KW - Clarithromycin

KW - Fluoroquinolone

KW - Gastric cancer

KW - H. pylori

KW - Metronidazole

UR - http://www.scopus.com/inward/record.url?scp=85033674013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033674013&partnerID=8YFLogxK

U2 - 10.1007/s00535-017-1407-1

DO - 10.1007/s00535-017-1407-1

M3 - Review article

C2 - 29138921

AN - SCOPUS:85033674013

SN - 0944-1174

VL - 53

SP - 354

EP - 361

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

IS - 3

ER -

World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this